Group 1 - The stock price of Boji Pharmaceutical closed at 11.98 yuan on August 21, 2025, down 3.07% from the previous trading day, with a trading volume of 567 million yuan and a turnover rate of 16.61% [1] - Boji Pharmaceutical operates in the healthcare services industry, with 99.39% of its revenue coming from service-related activities as reported in the 2024 financial report [1] - The controlling shareholder Wang Tingchun and his concerted parties plan to reduce their holdings by no more than 11.4865 million shares, accounting for 3% of the total share capital, due to personal funding needs [1] Group 2 - On August 21, the net outflow of main funds was 18.1492 million yuan, but over the past five days, the overall net inflow of main funds was 139 million yuan [1]

格隆汇7月30日丨博济医药(300404.SZ)在互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供医药研发外包服务并收取技术服务费，目前暂无基孔肯雅热病症的项目。 ...

格隆汇7月30日丨博济医药(300404.SZ)在互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供医药研发外包服务并收取技术服务费，目前暂无基孔肯雅热病症的项目。 ...

格隆汇7月30日丨博济医药(300404.SZ)在互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供医药研发外包服务并收取技术服务费，目前公司海外业务占比较小。 ...

格隆汇7月30日丨博济医药(300404.SZ)在互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供医药研发外包服务。当前公司在研的药物以创新药为主，涵盖化药、生物药、中药，涉及各 个药物治疗领域。此外，公司还可以提供医疗器械相关的临床试验及注册申报服务。 ...

证券日报网讯博济医药7月29日在互动平台回答投资者提问时表示，公司是一家专业的CRO服务提供 商，主要为医药企业提供医药研发外包服务并收取技术服务费。 （文章来源：证券日报） ...